News | November 30, 2010

BSGI/MBI Gains Recognition in Breast Cancer Detection and Diagnosis

November 30, 2010 - Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI) is gaining momentum as a standard of care in the diagnostic work up of patients. Several presentations at the 2010 Radiological Society of North America (RSNA) meeting will also show how the technology is an important diagnostic tool for early breast cancer detection.

Additionally, the Society of Nuclear Medicine (SNM) recently released a nuclear medicine breast imaging protocol that includes specific procedural guidelines and clinical indications for conducting BSGI/MBI.

BSGI/MBI is especially useful in difficult-to-diagnose cases such as ductal carcinoma in situ (DCIS), where mammography may not accurately display the extent of the disease. At RSNA researchers will demonstrate the sensitivity of BSGI for DCIS to be 93 percent to 95 percent for determining the extent of disease and varying pathological parameters.

“BSGI is a valuable tool that improves diagnostic accuracy, and complements other modalities, when included in the breast imaging protocol,” said Jocelyn A. Rapelyea, M.D., associate professor of radiology, George Washington University. “This modality is especially effective in assessing the extent of disease and assisting in surgical planning.”

The investigators of another study will demonstrate that BSGI is a useful tool for improving the detection of malignancies. They will also note that the physiological information of BSGI is complementary to the anatomical depiction of the breast by mammography and ultrasound.

The SNM Guidelines
In June 2010 the Society of Nuclear Medicine (SNM) released a nuclear medicine breast imaging protocol, The SNM Procedure Guideline for Breast Scintigraphy with Breast-Specific Gamma Cameras. This protocol includes specific guidelines for conducting BSGI and helps improve the understanding of how and when to use molecular breast imaging in patient care. For a complete review of the new SNM protocol for BSGI/MBI go to http://interactive.snm.org/docs/Breast_v2.0.pdf.

BSGI utilizes the Dilon 6800 Gamma Camera to help physicians differentiate benign from malignant tissue. To perform BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as dark spots on the BSGI image.

For more information: www.dilon.com.

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
Overlay Init